 IRVINE, Calif., Dec. 09, 2020 GLOBE NEWSWIRE -- Biomerica, Inc. Nasdaq: BMRA, a global provider of advanced medical products, today announced it is nearing completion of patient enrollment in the endpoint clinical trial for its InFoods Irritable Bowel Syndrome IBS diagnostic-guided therapy DGT. This double-blinded, randomized, controlled clinical trial is validating the Biomerica InFoods IBS test to manage the debilitating pain and suffering of patients diagnosed with IBS. Utilizing an antibody guided blood test, the InFoods IBS product identifies patient-specific foods that may alleviate IBS symptoms when eliminated from the diet. 